Research programme: AMPK activators - Ligand Pharmaceuticals/Merck

Drug Profile

Research programme: AMPK activators - Ligand Pharmaceuticals/Merck

Alternative Names: MB 07562

Latest Information Update: 29 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Hyperlipidaemia

Most Recent Events

  • 29 Jan 2010 Metabasis Therapeutics has been acquired by Ligand Pharmaceuticals
  • 11 Jun 2009 Merck selects a lead candidate for late preclinical development under its 4-year research collaboration agreement with Metabasis
  • 24 Apr 2008 Metabasis and Merck extend their collaboration for AMPK aktivators for diabetes and other metabolic diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top